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Abstract
Background: We conducted an exploratory study of genome-wide gene expression in whole blood and found that the
expression of neutrophil elastase inhibitor (PI3, elafin) was down-regulated during the early phase of ARDS. Further analyses
of plasma PI3 levels revealed a rapid decrease during early ARDS development. PI3 and secretory leukocyte proteinase
inhibitor (SLPI) are important low-molecular-weight proteinase inhibitors produced locally at neutrophil infiltration site in
the lung. In this study, we tested the hypothesis that an imbalance between neutrophil elastase (HNE) and its inhibitors in
blood is related to the development of ARDS.
Methodology/Principal Findings: PI3, SLPI, and HNE were measured in plasma samples collected from 148 ARDS patients
and 63 critical ill patients at risk for ARDS (controls). Compared with the controls, the ARDS patients had higher HNE, but
lower PI3, at the onset of ARDS, resulting in increased HNE/PI3 ratio (mean=14.5; 95% CI, 10.9–19.4, P,0.0001), whereas
plasma SLPI was not associated with the risk of ARDS development. Although the controls had elevated plasma PI3 and
HNE, their HNE/PI3 ratio (mean=6.5; 95% CI, 4.9–8.8) was not significantly different from the healthy individuals (mean=3.9;
95% CI, 2.7–5.9). Before the onset (7-days period prior to ARDS diagnosis), we only observed significantly elevated HNE, but
the HNE-PI3 balance remained normal. With the progress from prior to the onset of ARDS, the plasma level of PI3 declined,
whereas HNE was maintained at a higher level, tilting the balance toward more HNE in the circulation as characterized by an
increased HNE/PI3 ratio. In contrast, three days after ICU admission, there was a significant drop of HNE/PI3 ratio in the at-
risk controls.
Conclusions/Significance: Plasma profiles of PI3, HNE, and HNE/PI3 may be useful clinical biomarkers in monitoring the
development of ARDS.
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Introduction
Acute Respiratory Distress Syndrome (ARDS) is characterized
by inflammation of the lung parenchyma leading to impaired gas
exchange with concomitant systemic release of inflammatory
mediators [1]. It is one of the most common disease processes in
intensive care units (ICU), and is a major cause of morbidity and
mortality in the ICU throughout the world [2]. Despite the
development of clinical criteria for the diagnosis by American-
European Consensus Conference (AECC) on ARDS, there
remains a discrepancy between clinical criteria and histological
findings with a substantial proportion of patients with clinical
ARDS having no evidence of diffuse alveolar damage at autopsy
[3]. Due to the lack of specificity of the clinical definition, there
have been recent efforts to identify biological markers for diffuse
alveolar damage in pulmonary edema fluid, blood and urine
collected from critically ill patients with ARDS [4,5,6].
Previously we conducted an exploratory study of genome-wide
gene expression in whole blood samples from ARDS patients using
a repeated measures self-control study design to minimize noise
[7]. By comparing expression between the acute-stage and
recovery-stage of ARDS, we identified an ARDS-related gene
encoding a potent human neutrophil elastase inhibitor (PI3,
peptidase inhibitor 3, also known as elastase specific inhibitor,
skin-derived antileukoprotease, or elafin), which was down-
regulated during the acute-stage of ARDS. Analyses of plasma
PI3 levels revealed a rapid decrease during early ARDS
development, which was well correlated with PI3 gene expression.
Neutrophil elastase (HNE) is one of the most destructive enzymes
with the capability of degrading almost all extracellular matrix and
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iology of ARDS [8,9]. We only observed HNE expression in few
blood samples while majority of samples did not express this gene
in the same study. This observation is consistent with previous
findings that HNE gene is mainly expressed at the promyelocytic
stage of granulocyte development, and mRNA cannot be detected
in circulating neutrophils [10,11].
A high concentration of HNE is stored in azurophil granules of
neutrophils, providing a powerful host defense. Upon activation,
however, HNE can be released rapidly into the extracellular space
and cause tissue damage [9]. Endogenous proteinase inhibitors are
important to protect tissues from unregulated proteolysis. Once
released in circulation, HNE is rapidly inactivated by conjugating
with protease inhibitors, mostly high-molecular-weight inhibitors
including a1-antitrypsin and a2-macroglobulin [9]. Whereas low-
molecular-weight inhibitors, such as elafin (PI3) and secretory
leukocyte proteinase inhibitor (SLPI), are especially critical in local
protection by their capability of penetrating into the ‘‘microenvi-
ronment’’ created by neutrophil to sequester HNE from high-
molecular-weight inhibitors [12]. A local imbalance between
proteinases and inhibitors results in pulmonary parenchyma
damage by leakage of a protein-rich fluid into the interstitium
and alveolar spaces, which is the major mechanism for activated
neutrophils initiating and propagating ARDS [8].
PI3and SLPI are the only members of low-molecular-weight
proteinase inhibitor family produced locally at the site of
neutrophil infiltration such as lung [13,14]. In contrast to SLPI,
PI3 has a narrower spectrum of inhibition specifically toward
HNE and proteinases 3 [14]. In addition, PI3 molecule has a
unique N-terminal structure containing several transglutaminase
substrate motifs that can bind the whole molecule to extracellular
matrix (ECM) proteins via covalent cross-linking [15], and the
covalently bound PI3 can still inhibit HNE [16]. Thus, PI3 can
provide more efficient local protection against HNE in lung. It is
very difficult to assess precisely the pulmonary level of PI3 in acute
lung injury (ALI) or ARDS, as most of PI3 is anchored to lung
parenchyma and exerts its biological functions locally [17]. We
hypothesized that the plasma changes of low-molecular-weight
proteinase inhibitors (PI3 and SLPI) and their antagonist HNE
can be used as surrogate markers in monitoring the clinical
progress of ARDS. More specifically, the disruption of the balance
between proteinase inhibitors and HNE toward excessive HNE in
circulation might be correlated with ARDS development.
Therefore, we conducted a comprehensive investigation of plasma




We analyzed the plasma levels of PI3, SLPI, and HNE in
ARDS patients and at-risk controls to investigate the hypothesis
that plasma changes of proteinase inhibitors (PI3 and SLPI) and
their antagonist HNE can be used as surrogate markers in
monitoring the clinical progress of ARDS.
Participants
This study was conducted within the ongoing project, the
Molecular Epidemiology of ARDS, at the Massachusetts General
Hospital (MGH) in Boston, Massachusetts, which is a prospec-
tively-enrolled cohort study of ARDS [18]. The flowchart of study
design is illustrated in Online Supplementary Material, Figure S1.
Briefly, all patients enrolled from adult ICU at MGH are at risk
for the development of ARDS with well-characterized predispos-
ing clinical conditions, and are followed prospectively for the
development of ARDS during their ICU stay [19,20]. Predispos-
ing clinical conditions are: 1) sepsis, 2) septic shock, 3) trauma, 4)
pneumonia, 5) aspiration, or 6) massive transfusion of packed red
blood cells (PRBC: defined as greater than 8 units of PRBC during
the 24 hours prior to admission) as previously described [18].
Patients with previous history of ARDS and previous enrollment
as controls were excluded. ARDS cases were defined by the AECC
criteria [3]. Controls were identified as at-risk patients who did not
meet criteria for ARDS during their ICU stay and had no prior
history of ARDS. Exclusion criteria included age ,18; diffuse
alveolar hemorrhage; chronic lung diseases other than COPD or
asthma; directive to withhold intubation; and treatment with
immunosuppressive agent or immunoenhancing agent such as
granulocyte colony-stimulating factor in the preceding 21 days.
Ethics
The study was approved by the Human Subjects Committee of
MGH. A written informed consent was obtained from each
patient or an appropriate proxy.
Clinical Data
Baseline clinical information, vital signs, and laboratory testing
results in the first 24 hours of ICU admission were collected for
calculation of the Acute Physiological and Chronic Health
Evaluation (APACHE) III score [21]. In addition to a blood
collection for DNA extraction during ICU stay, plasma samples
were also collected for long-term storage.
Plasma Sample Collection
Based on the original sampling protocol, plasma was collected
from each enrolled patient within 48 hours of ICU admission, and
a second sample was collected three days later. If an enrolled
patient developed ARDS, two additional samples were collected
corresponding to the first 48-hour of ARDS diagnosis and three
days later. However, given the critical condition of ICU patients,
difficulties in identifying surrogates and obtaining consent in time,
the limitation of total blood drawn from each subject set by the
IRB, as well as depletion from our previous study, only a fraction
of enrolled patients had plasma available in this study (Online
Supplementary Material, Figure S1). Since over 90% of ARDS
cases developed ARDS during the first 7 days of ICU admission,
the plasma from ARDS patients could be divided into three
groups, the pre-ARDS samples (up to 7 days before ARDS
diagnosis, n=19), the ARDS samples (within 48 hours of
diagnosis, n=67), and the post-ARDS samples (day 2 to 4 of
diagnosis, n=105). In the current study, we excluded three
samples collected more than 8 days before ARDS diagnosis and
used the rest of available samples from ARDS cases, including 191
plasma samples from 148 ARDS patients. In addition, for the
purpose of investigating temporal changes, we included paired
plasma samples from the controls without ARDS, corresponding
to the sampling time points within 48 hours of ICU admission and
three days later after the first collection. Sixty-four control patients
were selected randomly from 176 controls with paired plasma.
Furthermore, 28 anonymous plasma samples collected from
healthy male Caucasians were included as reference samples.
ELISA Analysis of Plasma Profiles
Plasma samples were stored at 280uC until analysis. Plasma PI3,
SLPI, and HNE levelswere quantified in duplicate using Human pre-
ELAFIN/SKALP (Cat. No. HK318), Human SLPI (Cat No.
HK316), and Human Elastase (Cat No. HK319) ELISA Test Kit
HNE-PI3 Imbalance in ARDS
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recommended protocol. Except one control plasma sample which
were excluded from the analyses, the CVs of replicates for the rest of
samples were under 13%, which were below the manufacturer’s
recommended 15% standard. Eleven plasmasamples were randomly
selected as replicates for quality evaluation, and we had the inter-
assay CVs ranging from 4% to 25%.
Statistical analysis
The baseline characteristics between groups were compared
using chi-square tests for categorical variables, and two sample t-
tests for continuous variables. The normality of continuous
variables was tested using Kolmogorov-Smirnov and Anderson-
Darling methods. Since plasma profiles of PI3, SLPI, HNE, and
HNE/PI3 ratio had skewed distributions, the natural log
transformed data were applied to adjust normality in the analyses.
Plasma profiles among different sample groups were compared by
the two sample t-test, ANOVA (general linear model), and the
mixed effect model for repeated samples. Paired t-test and
Wilcoxon sign-rank test were used as well to analyze the paired
samples from controls. In ANOVA analyses, Bonferroni correction
was used to adjust for multiple comparisons. The relationship
between ARDS plasma profiles and the sampling date relative to
ARDS diagnosis was investigated by mixed effect models. Clinical
relevant covariates were adjusted in the analyses, including age,
gender, type of lung injury (pulmonary vs. extrapulmonary injury),
pre-admission steroid use, septic shock, and APACHE III score on
ICU admission. Patients with pneumonia, aspiration, pulmonary
contusions, or sepsis from lower pulmonary source were
categorized as pulmonary injury; whereas, patients with sepsis
from an extrapulmonary source, trauma without pulmonary
contusions, and multiple transfusions were categorized as extra-
pulmonary injury. Patients with both pulmonary and extrapul-
monary injuries were considered to have pulmonary injury. All
statistical analyses were performed by using the SAS statistical
software package (version 9.1, SAS Inc., Cary, NC).
Results
Baseline Characteristics of the Study Population
Of 1,695 enrolled patients who had ARDS risk factors and no
exclusion criteria by the end of 2007, 513 patients eventually
developed ARDS during ICU hospitalization. Baseline character-
istics between the selected ARDS cases and controls, as shown in
Table 1, were similar to those published in previous studies within
the similar study population [18,22]. There were 191 plasma
samples collected from 148 ARDS patients available in the present
study. When the ARDS patients with plasma samples were
compared to those without plasma samples, there were no
significant differences with regard to age, gender, ethnicity, or
other relevant baseline characteristics (P.0.05 for all compari-
sons). However, the studied ARDS cases had significantly higher
proportions of pneumonia, pulmonary injury, and pre-admission
steroid use, as well as higher APACHE III score on ICU admission
(Online Supplementary Material, Table S1). Sixty-four critically ill
patients with ARDS risk factors randomly selected as controls had
baseline characteristics that were not significantly different from
the unselected controls (P.0.05 for all comparisons) except that
selected controls had a higher APACHE III score on ICU
admission (P=0.027) (Online Supplementary Material, Table S2).
Since the paired plasma from one control failed to generate
reliable plasma profiles, we excluded this subject resulting in 63
Table 1. Characteristics of the study population
ARDS (n=148) At-risk controls (n=64) P
Age-yr, mean6SD 60619 61617 0.730
Gender, male/female 90/58 38/26 0.844
Caucasian, n (%) 140 (94.4) 61 (95.3) 0.829
APACHE III score, mean6SD
a 81622 72623 0.006
On ventilation at ICU admission, n (%) 131 (88.5) 40 (62.5) ,0.0001
Risk factors, n (%)
Sepsis 134 (90.5) 52 (81.3) 0.058
Septic shock 89 (60.1) 28 (43.8) 0.028
Pneumonia 118 (79.7) 25 (39.1) ,0.0001
Aspiration 14 (9.5) 6 (9.4) 0.985
Pulmonary injury
b 125 (84.5) 31 (48.4) ,0.0001
Multiple transfusion 10 (6.8) 7 (10.9) 0.304
Trauma 7 (4.7) 6 (9.4) 0.196
Comorbidities, n (%)
Diabetes 28 (18.9) 15 (23.4) 0.452
Liver failure/cirrhosis 10 (6.8) 3 (4.7) 0.564
Corticosteroid treatment before ICU admission, n (%)
c 26 (17.6) 4 (6.3) 0.030
ARDS, acute respiratory distress syndrome; APACHE, Acute Physiology and Chronic Health Evaluation;
a. APACHE III physiology score was calculated with all components on the day of ICU admission;
b. Pneumonia, aspiration, pulmonary contusions, or sepsis from lower pulmonary source were categorized as pulmonary injury. Sepsis from an extrapulmonary source,
trauma without pulmonary contusions, and multiple transfusions were categorized as extrapulmonary injury. Patients with both pulmonary and extrapulmonary
injuries were considered to have pulmonary injury;
c. Patient received $ 300 mg of prednisone or its equivalent within 21 days or $ 15 mg prednisone a day or its equivalent prior to ICU admission.
doi:10.1371/journal.pone.0004380.t001
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significant changes in the baseline characteristics of the controls
(data not shown). The reference group included anonymous
plasma samples from male healthy donors, which were significant
younger than the studied population (mean age6SD: 40611;
P,0.0001).
Correlations among Plasma Profiles in the ARDS and the
Control
Plasma profiles of PI3, SLPI, and HNE on 67 ARDS plasma
samples collected within 48-hour of diagnosis were compared with
the profiles on 63 control samples collected within 48-hour of ICU
admission. The correlation matrix of plasma profiles and
APACHE III scores were shown in Online Supplementary
Material, Table S3. Plasma PI3 correlated with plasma SLPI in
the ARDS samples (Pearson correlation coefficient: r=0.37,
P=0.004) and in the control samples where the correlation was
stronger (r=0.50, P,0.0001). In contrast, plasma PI3 had a
moderate correlation with plasma HNE in the ARDS sample
(r=0.42, P=0.0009), but not in the control sample (r=0.03,
P=0.815) (Online Supplementary Material, Figure S2). In both
the ARDS and the control, plasma PI3 and SLPI demonstrated
moderate correlations with APACHE III score on ICU admission
(r=0.34–0.51, P,0.01 for all analyses), but plasma HNE only
showed correlation with APACHE III score in the ARDS samples
(r=0.51, P,0.0001). Since plasma PI3 and HNE showed some
different correlations between the ARDS samples and the control
samples, we proposed to combine two variables by calculating the
ratio of HNE/PI3 and included it in the subsequent analyses. The
HNE/PI3 ratio was not correlated with APACHE III score in
both ARDS cases and controls.
Comparison of Plasma Profiles between ARDS and
Controls
As shown in Table 2, both the ARDS samples (n=67, 48-hour
of ARDS diagnosis) and the ICU control samples (n=63, 48-hour
of ICU admission) had significantly elevated plasma levels of PI3,
SLPI, and HNE (P,10
26 for all comparisons, two sample t-tests),
as compared with the reference plasma samples from healthy
individuals (n=28). When compared with the controls on ICU
admission in two sample t-tests, there were significantly higher
levels of plasma HNE (P=0.007) and HNE/PI3 ratio (P=0.001)
at ARDS diagnosis, but no significant difference in plasma SLPI
(P=0.657). The ARDS samples had a lower plasma PI3 but did
not show statistical significance (P=0.115). After adjusting for age,
gender, type of lung injury, septic shock, pre-admission steroid use,
and APACHE III score on ICU admission, there was a
significantly lower level of plasma PI3 in the ARDS, whereas the
remaining test results were unchanged (Table 2). The opposite
changes of PI3 and HNE between the ARDS and the control,
which resulted in a highly increased HNE/PI3 ratio, suggested
that the balance between neutrophil elastase and its inhibitor was
severely damaged with elastase dominant in blood at the onset of
ARDS. In contrast, the HNE/PI3 ratio was not statistically
significant different between the controls and the reference
samples (two sample t-test, P=0.105).
In subgroup analyses within different types of lung injury, we
only found similar significant changes in plasma profiles of PI3 and
Table 2. Plasma profile comparison between ARDS and controls







PI3 44.3 (35.0–56.0) 69.3 (54.4–88.2) 0.005 19.6 (13.9–27.5)
SLPI 115.3 (101.2–131.5) 132.5 (115.8–151.7) 0.752 69.6 (62.3–77.9)
HNE 643.6 (525.3–788.7) 453.3 (367.6–558.9) 0.017 77.1 (63.9–93.1)
HNE/PI3 ratio 14.5 (10.9–19.4) 6.5 (4.9–8.8) ,0.0001 3.9 (2.7–5.9)
Pulmonary injury
b N=54 N=30
PI3 44.6 (35.6–55.9) 81.7 (60.2–110.8) 0.001
SLPI 126.2 (112.0–142.3) 140.7 (119.6–165.4) 0.221
HNE 546.2 (447.5–666.7) 396.3 (302.6–519.1) 0.107
HNE/PI3 ratio 12.2 (9.3–16.1) 4.9 (3.3–7.0) ,0.0001
Extrapulmonary injury
b N=13 N=33
PI3 66.7 (36.2–122.9) 77.9 (44.9–135.3) 0.480
SLPI 108.6 (74.0–159.3) 136.9 (96.9–193.5) 0.655
HNE 639.9 (376.7–1087.1) 491.0 (304.5–791.6) 0.655
HNE/PI3 ratio 13.7 (4.5–20.3) 6.3 (3.2–12.4) 0.254
ARDS, acute respiratory distress syndrome; Control, at-risk ICU control; PI3, neutrophil elastase inhibitor (elafin); SLPI, secretory leukocyte proteinase inhibitor; HNE,
neutrophil elastase; the plasma levels of PI3, SLPI, and HNE were shown in unit of ng/ml; 95%CI, 95% confidence interval.
a. To account for repeated measurements, mean plasma levels were calculated using mixed models after adjusting for age, gender, type of lung injury, pre-admission
steroid use, septic shock, and APACHE III score on ICU admission. Type of lung injury: pulmonary injury - pneumonia, aspiration, pulmonary contusions, or sepsis from
lower pulmonary source; extrapulmonary injury - sepsis from an extrapulmonary source, trauma without pulmonary contusions, and multiple transfusions. Patients
with both pulmonary and extrapulmonary injuries were considered to have pulmonary injury.
b. To account for repeated measurements, mean plasma levels were calculated using mixed models after adjusting for age, gender, pre-admission steroid use, septic
shock and APACHE III score on ICU admission.
c. P values were calculated between the ARDS and the controls.
d. Mean plasma levels of anonymous healthy individuals (reference groups) were calculated directly without any adjustment.
doi:10.1371/journal.pone.0004380.t002
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nary injury group (Table 2). Moreover, either in the ARDS or in
the controls, we did not observe any significant difference of
plasma profiles between different types of lung injury.
Plasma profiles among pre-ARDS, ARDS and controls
Toexploretheusefulnessofusingplasmaprofilestopredicttherisk
of ARDS development, we focused initially on the samples collected
on ICU admission (first 48-hour). Only a fraction of ARDS patients
were diagnosed during the first 48-hour of ICU admission, whereas,
the rest were diagnosed later during the ICU hospitalization. Thus,
samples collected on ICU admission could be classified into three
groups, including pre-ARDS, ARDS and control patients who did
not develop ARDS during ICU stay. However, out of 191 ARDS
samples available in this study, we only identified 28 plasma samples
which had been collected on ICU admission, including 7 pre-ARDS
samples and 21 ARDS samples. Considering relatively small number
of samples in the pre-ARDS group and ARDS group collected on
ICU admission, we combined all available pre-ARDS samples
(n=19) and ARDS (within 48-hour diagnosis, n=67) in the analyses.
The plasma PI3, HNE and HNE/PI3 were statistically significant
different among three groups in both crude analyses (ANOVA,
P=0.004, 0.007, and 0.0004, respectively), and in the adjusted
analyses with age, gender, pulmonary injury, pre-admission steroid
use, and higher APACHE III score on ICU admission (general linear
model, P=0.0005, 0.006, and ,0.0001, respectively). There was no
significant difference of plasma SLPI among three groups in crude
analysis (ANOVA: P=0.943) and adjusted analysis (general linear
model, P=0.115). In pairwise comparisons with Bonferroni
correction for multiple testing, firstly, we found similar changes of
plasma profiles between the ARDS and the controls, with plasma
HNE and HNE/PI3 ratio significant higher in the ARDS, but PI3
did not reach significance after correction for multiple comparisons
(Figure1).Secondly, when comparing the pre-ARDS and the ARDS,
Figure 1. Box plot of plasma profiles of PI3, SLPI, HNE, and HNE/PI3 among pre-ARDS, the ARDS and the controls. Pre-ARDS: plasma
sample (n=19) collected during 7-day period before ARDS diagnosis; ARDS: samples (n=67) collected within 48-hour of ARDS diagnosis; Control:
samples (n=63) collected within 48-hour of ICU admission; Ref: anonymous plasma samples from healthy individual (n=28). The plasma profiles
among three groups were tested by general linear model with adjustment of age, gender, pulmonary injury, pre-admission steroid use, and higher
APACHE III score on ICU admission (P values showed in the plots).
doi:10.1371/journal.pone.0004380.g001
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HNE/PI3 ratio than the pre-ARDS group. However, there was no
significant difference in HNE between the pre-ARDS and the ARDS
samples. Finally, the plasma HNE in pre-ARDS was significantly
higher than the controls (P=0.018), but no significant difference of
plasma PI3, SLPI, and HNE/PI3 ratio was observed between two
groups (Table 3). Furthermore, although the pre-ARDS had
significantly higher PI3, SLP, and HNE than the reference samples
(P,10
26 for all comparisons, two sample t-tests), the HNE/PI3 ratio
was not significantly different between two groups (P=0.276, two
sample t-tests). In summary, these findings indicated that the balance
between PI3 and HNE was maintained before the onset of ARDS.
Decrease of plasma PI3 with the clinical progress of ARDS
Our previous results suggested that reduction of PI3 along with
the clinical progress of ARDS might be the cause for disrupting the
HNE-PI3 balance. Next, we looked the changes of plasma profiles
among three sample groups from ARDS patients, including pre-
ARDS, at ARDS diagnosis, and post-ARDS diagnosis. The PI3
and HNE/PI3 were significant changed among three groups in
both the crude analyses (ANOVA, P=0.004 and P=0.010,
respectively), and in the analyses adjusted for age, gender,
pulmonary injury, pre-admission steroid use, and APACHE III
score on ICU admission (general linear model, P=0.015 and
P=0.036, respectively). The pre-ARDS samples had significant
higher PI3, but lower HNE/PI3, than either the ARDS or the
post-ARDS in pairwise comparisons after correction for multiple
testing (Figure 2). In contrast, there was no difference in plasma
SLPI and HNE among three samples groups. We further tested
the trend of plasma PI3 decrease across ARDS development, as
measured by sampling dates relative to ARDS diagnosis, using
mixed effect models. The reciprocal of days between sampling
dates relative to ARDS diagnosis was significantly related to
plasma PI3 and HNE/PI3 (mixed models, P=0.001 and
P=0.010, respectively), suggesting that the closer to ARDS onset,
the greater the decrease in PI3 and the higher degree of HNE/PI3
imbalance.
Changes of plasma profiles between paired samples of
controls
The changes in plasma profiles in control patients who did not
develop ARDS during ICU stay were investigated between paired
samples collected within 48 hours of ICU admission and three
days after the first sample collection (Table 4). As compared with
the ICU admission, the second plasma had significant lower HNE
(paired t-test, P=0.003; Wilcoxon sign-rank test, P=0.0008),
accompanied by a lower HNE/PI3 ratio (paired t-test, P=0.001;
Wilcoxon sign-rank test, P=0.0004). This observation suggests
that the elevated plasma HNE was decreased in those patients who
did not develop ARDS. Interestingly, we found the plasma profiles
changed differently by type of lung injury, while the final results
were in favor of maintaining enough inhibition capacity against
HNE. In the patients with pulmonary injury, there was a
significant decrease of HNE (P=0.023) without significant
changes in PI3 (P=0.302). Conversely in the patients with
extrapulmonary injury, there was a significant increase of PI3
(P=0.023) without significant changes in HNE (P=0.069).
Twenty-four ARDS patients provided paired plasma in the
study, with the first sample collected during the first 48 hours of
ARDS diagnosis and second sample collected three days later.
However, there was no significant change in PI3 (P=0.132), SLPI
(P=0.226), HNE (P=0.552), and HNE/PI3 (P=0.083) between
two time points.
Table 3. ANOVA analyses of plasma profiles among the pre-ARDS, ARDS and the Control
a




Control NA ++ + 80.3 (66.7–96.6)
Pre-ARDS NA ++ 87.5 (61.0–125.5)
ARDS NA 52.9 (42.7–65.6)
SLPI 0.187
Control NA - - 139.4 (126.1–154.0)
Pre-ARDS NA - 125.2 (103.6–151.4)
ARDS NA 120.7 (107.6–135.5)
HNE 0.012
Control NA ++ + 447.5 (380.6–526.2)
Pre-ARDS NA - 643.4 (472.8–875.7)
ARDS NA 633.0 (524.8–763.6)
HNE/PI3 0.0001
Control NA - ++ 5.6 (4.4–7.0)
Pre-ARDS NA ++ 7.5 (4.8–11.7)
ARDS NA 12.0 (9.2–15.6)
ARDS, acute respiratory distress syndrome; PI3, neutrophil elastase inhibitor (elafin); SLPI, secretory leukocyte proteinase inhibitor; HNE, neutrophil elastase; 95%CI, 95%
confidence interval.
a. ANOVA analysis plasma profiles using general linear model with adjustment of covariates, including age, gender, type of lung injury, pre-admission steroid use, septic
shock, and APACHE III score on ICU admission. Pairwise comparison: ++,P ,0.05 after Bonferroni correction for multiple comparisons; +, P,0.05 without Bonferroni
correction; -, P$0.05; NA, not applicable.
b. P values of general linear model for all groups.
c. The unit of HNE/PI3 is fold change.
doi:10.1371/journal.pone.0004380.t003
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Previous research showed that a local imbalance between
proteinases and their physiological inhibitors damage the pulmo-
nary parenchyma resulting in leaking a protein-rich fluid into the
interstitium and alveolar spaces, a process that plays a crucial role
in the initiation and propagation of ARDS [9]. Our study extends
this observation into the peripheral circulation. At the onset of
ARDS, the ARDS patients had significantly higher HNE but
lower PI3 resulting in increased HNE/PI3 ratio (mean=14.5;
95% CI, 10.9–19.4), compared with patients who did not develop
ARDS during the ICU hospitalization which had a higher but not
statistically significant HNE/PI3 ratio (mean=6.5; 95% CI, 4.9–
8.8) than that of healthy individuals (reference samples:
mean=3.9; 95% CI, 2.7–5.9). Before the ARDS onset (7-day
period prior to ARDS diagnosis), we observed only a significantly
elevated HNE, but an unchanged HNE/PI3 ratio as compared
with either the at-risk controls at the ICU admission or the healthy
reference group. With the progress of acute lung injury from prior
to the onset of ARDS, the PI3 plasma level was dropped whereas
HNE was maintained at a higher level, tilting the balance toward
more neutrophil elastase in the circulation characterized by
increased HNE/PI3 ratio. In contrast, three days after ICU
admission, there was a significant drop of the HNE/PI3 ratio in
the at-risk controls. Therefore, these results suggest that the loss of
the balance between plasma neutrophil elastase (HNE) and its
specific inhibitor elafin (PI3) is related to the risk of ARDS
development. Furthermore, the plasma profiles of PI3, HNE, and
HNE/PI3 can be used as clinical biomarkers in monitoring the
development of ARDS. However, plasma SLPI was not associated
with the risk of ARDS development.
Although both PI3 and SLPI are low-molecular-weight protein-
ase inhibitors belonging to the same chelonianin family of canonical
inhibitors (Family I17 Clan IP in the MEROPS database), PI3 has a
Figure 2. Box plot of plasma profile changes in clinical progress of ARDS. Pre-ARDS: plasma sample (n=19) collected during 7-day period
before ARDS diagnosis; ARDS: samples (n=67) collected within 48-hour of ARDS diagnosis; Post-ARDS: samples (n=105) collected between Day 2
and Day 4 of ARDS diagnosis. The trends of plasma profiles across ARDS development, as measured by reciprocal of days between sampling dates
relative to ARDS diagnosis, were tested by mixed effect models, adjusted for age, gender, type of pulmonary injury, pre-admission steroid use, and
APACHE III score on ICU admission (P values showed in the plots).
doi:10.1371/journal.pone.0004380.g002
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neutrophil elastase and proteinase 3 [14]. In addition, PI3 has a
unique N-terminal non-inhibitory domain, containing several
transglutaminase substrate motifs, which can covalently anchor
the whole molecule to extracellular matrix (ECM) protein through
protein cross-linking [15,16]. Small molecular size, specific anti-
elastase spectrum, and immobilization to ECM are major
characteristics that determine how PI3 plays critical protective
roles against the tissue damage induced by HNE during acute lung
injury. The expression of PI3 gene can be readily induced under
inflammatoryconditionsbypro-inflammatorycytokines,such asIL-
b1 and TNF-a, and elastase [23,24,25]. Our previous genome-wide
gene expression analysis revealed that PI3 gene demonstrated the
largest down-regulation in peripheral blood expression at the early
stage of ARDS, as compared with the recovery stage around ICU
discharge [7]. In a smaller set of samples (40 ARDS patients and 23
at-risk controls), the protein expression in plasma correlated well
with the microarray findings, with a lower level of plasma PI3
during the acute-stage. In the same study, we were first to report
that there was a trend of plasma PI3 decreasing from pre- to post-
diagnosis of ARDS. The results of this study confirmed our previous
studyby observing the same PI3decreasingtrend along with clinical
progress toward ARDS development, with a larger sample size
within the same study population (148 ARDS patients and 63
controls). We conducted additional analyses of plasma PI3 by
pooling data from both studies, which had overlapped samples
collected from 24 ARDS patients and 13 at-risk controls, and
obtained consistent results (data not shown).
At another end of proteinase-inhibitor balance is the HNE,
which has been implicated in the pathogenesis of ALI/ARDS in
previous studies [26]. Elevated HNE was observed in animal
models of ALI. Administration of HNE could induce typical
symptoms of ALI in experiment animals, and inhibition of
increased HNE could reduce ALI symptoms [9,27]. Despite
earlier clinical studies revealing conflicted results of elevated HNE
in bronchoalveolar lavage fluid [8,28,29], more recent studies
measuring plasma HNE found consistently increased plasma HNE
in ALI/ARDS patients [30,31,32,33]. Our observations of
significantly higher plasma HNE in the ARDS patients were
consistent with the previous research. In one particular study
examining sequential blood samples, Kodama et al. reported that
the plasma HNE level of ALI/ARDS patients (n=18) with
inflammatory response syndrome (SIRS) was significantly greater
than that of SIRS alone (n=5) [34]. A cut off value of .220 ng/
ml was also proposed in the same study, as HNE in all patients
with SIRS alone was consistently less than this value and all SIRS
patients with HNE more than 220 ng/ml eventually developed
ALI/ARDS. Because of a small sample size, that study pooled ALI
and ARDS together as the case group to compare with a patient
group having less severe conditions. This may explain why the
majority of controls in our study had plasma HNE higher than the
Kodama’s cut off value, as many control patients in our study
already developed ALI. Nevertheless, our findings that significant
elevated HNE before the onset of ARDS (the pre-ARDS) agrees
with a previous report that the onset of pulmonary dysfunction
followed HNE increase.
Table 4. Changes of plasma profiles between paired samples
First Sample
a Mean (95% CI) Second Sample
b Mean (95%CI) P
c
Control (all samples, n=63)
PI3 73.1 (58.9–90.7) 76.9 (63.4–93.3) 0.335
SLPI 133.6 (118.8–150.1) 119.7 (106.8–134.2) 0.019
HNE 421.8 (351.5–506.1) 329.8 (276–394.1) 0.003
HNE/PI3 ratio 5.8 (4.4–7.6) 4.3 (3.3–5.5) 0.001
Control (pulmonary injury, n=30)
PI3 88.2 (62.3–124.7) 81.6 (58.4–113.9) 0.302
SLPI 147 (125.4–172.2) 133.9 (115.4–155.4) 0.164
HNE 351.8 (268.6–460.7) 262.7 (202.5–340.9) 0.023
HNE/PI3 ratio 4.0 (2.6–6.2) 3.2 (2.1–4.9) 0.115
Control (extrapulmonary injury, n=33)
PI3 61.6 (47–80.7) 73 (58.1–91.6) 0.023
SLPI 122.4 (103–145.5) 108.1 (91.1–128.3) 0.063
HNE 497.4 (388.8–636.5) 405.6 (321.1–512.4) 0.069
HNE/PI3 ratio 8.1 (5.8–11.3) 5.6 (4.1–7.5) 0.004
ARDS (all samples, n=24)
PI3 48.9 (31.4–76) 57.5 (38.9–85.1) 0.132
SLPI 122.1 (101.3–147.1) 130.5 (104–163.9) 0.226
HNE 561 (414.4–759.4) 522.5 (421.3–648) 0.552
HNE/PI3 ratio 11.5 (7.7–17) 9.1 (6.1–13.6) 0.083
PI3, neutrophil elastase inhibitor (elafin); SLPI, secretory leukocyte proteinase inhibitor; HNE, neutrophil elastase; the plasma levels of PI3, SLPI, and HNE were shown in
unit of ng/ml; 95%CI, 95% confidence interval.
a. For at-risk control patients, the first plasma samples were collected within 48-hour of ICU admission; For ARDS patients, the first plasma samples were collected within
48-hour of ARDS diagnosis.
b. The second samples were collected three days after the first collection.
c. Paired t-test
doi:10.1371/journal.pone.0004380.t004
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could be used as a predictive factor for ALI/ARDS development,
patients with predisposing risk conditions for ARDS often had
increased plasma HNE with a large range of variation. Similarly,
despite the fact that we observed a significant lower level of plasma
PI3 in the ARDS patients, there was a wide range of variation in
both ARDS patients and the at-risk controls. PI3 and HNE are
located at the opposite ends of the proteinase-inhibitor balance,
and their expression levels could be affected by common as well as
independent factors. In clinical practice, it is difficult to define a
clear cutoff point to distinguish ARDS patients from those
critically ill patients who did not develop ARDS by monitoring
a single biomarker, which only depicts a half picture of the
balance. Instead, simultaneous measurement of a group of
functionally related biomarkers will be more practical to assess
comprehensive status of ARDS. Since it is impractical to assess
local HNE-PI3 balance in lung, monitoring the plasma HNE-PI3
balance is a good alternative.
We propose that the biological mechanism for our results is that,
with the progress of pulmonary inflammation, the increased
permeability allows free passing of HNE and PI3 through
pulmonary blood-gas barrier. The change of plasma PI3 could
be explained by the redistribution of PI3 from blood stream to
local site. It is more likely that PI3 has a net unidirectional flow
from blood to lung parenchyma as PI3 will be trapped in ECM by
transglutaminase-catalyzed cross-links. Elevated circulating PI3
acts as an extra-pulmonary resource for protecting unregulated
proteolysis. When plasma PI3 drops to certain level, HNE-PI3
balance cannot be maintained in both circulation and lung with
the occurrence of ARDS. Additional studies are needed to test this
hypothesis. Furthermore, this hypothesis may explain why a large
multicenter clinical trial of sivelestat, a specific elastase inhibitor,
failed to improve the survival rate of ALI/ARDS [35]. In that
study, all patients were enrolled after the onset of ALI, which could
have been too late for the action of an elastase inhibitor. In
another smaller clinical trial, sivelestat was administrated from the
ICU admission resulting in significant reduction of mortality in
critically ill patients [36]. On the other hand, our hypothesis also
suggests that PI3 itself may be a drug candidate for specific ARDS
treatment.
All patients enrolled in the present study were at risk for the
development of ARDS because of well-characterized predisposing
clinical conditions, and were followed prospectively for the
development of ARDS during their ICU hospitalization. This
unique feature of the study design allowed us to investigate plasma
profiles before the onset of ARDS. However, we acknowledge a
limitation that the sample size of this study was relative small,
especially in the pre-ARDS group. In addition, although paired
sampling is a powerful study design in controlling the confounders,
most of the repeated samples from the ARDS patients were the
ARDS samples and the post-ARDS samples, without many the
pre-ARDS sample. Thus, confirmatory studies with large sample
sizes are required to validate this study. Moreover, we only
measured the amount of total HNE in circulation, which was
mostly conjugated with high-molecular-weight inhibitors, instead
of assessing directly the HNE activity. Measuring HNE-inhibitor
complex is commonly used for monitoring circulating HNE
activity, as there is a high correlation between them [37].
Nevertheless, the level of conjugated complex between HNE and
high-molecular-weight inhibitors did not systematically correlate
with severity of illness [8].
Supporting Information
Figure S1 Flow diagram of study design and sample selection.
All admissions to the adult ICUs at the MGH in Boston,
Massachusetts were screened on a daily basis to identify and
recruit patients with one or more clinical conditions (risk factors)
that are associated with ARDS, including sepsis, septic shock,
pneumonia, trauma (multiple fractures and/or pulmonary contu-
sions), multiple transfusions, and aspiration. All recruited patients
were then followed on a daily basis for the development of ARDS,
according to the AECC definition. All chest x-rays had been
interpreted by two physicians blinded to the clinical conditions of
the patient and any disagreement were decided by a third
physician. Cases were identified as those who developed ARDS at
anytime during their ICU stay, and controls were those who did
not develop ARDS during their ICU hospitalization with no
previous history of ARDS. According to sampling protocol,
plasma was collected from each enrolled patient within 48 hours
of ICU admission, and a second sample was collected three days
later. If an enrolled patient developed ARDS, two additional
samples were collected corresponding to the first 48-hour of
ARDS diagnosis and three days later. However, given the critical
condition of ICU patients, difficulties in identifying surrogates and
obtaining consent in time, the limitation of total blood drawn from
each subject set by the IRB, and the use of plasma samples in
previous studies, only fraction of enrolled subjects had plasma
samples available for this study.
Found at: doi:10.1371/journal.pone.0004380.s001 (0.08 MB TIF)
Figure S2 Plot of plasma PI3 against HNE. Plasma PI3 and
HNE were log transformed. ARDS: 67 samples collected within
48-hour of ARDS diagnosis; Control: 63 samples collected within
48-hour of ICU admission; Ref: 28 anonymous plasma samples
from healthy individual.
Found at: doi:10.1371/journal.pone.0004380.s002 (0.06 MB TIF)
Table S1 Compare characteristics between ARDS cases with
plasma samples and those without plasma (excluded in this study)
Found at: doi:10.1371/journal.pone.0004380.s003 (0.06 MB
DOC)
Table S2 Compare characteristics between at-risk controls
selected in this study and those excluded
Found at: doi:10.1371/journal.pone.0004380.s004 (0.06 MB
DOC)
Table S3 Correlation coefficients (p value) among plasma
profiles and APACHE III score
Found at: doi:10.1371/journal.pone.0004380.s005 (0.07 MB
DOC)
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